The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude

This study will include men and women who meet the following inclusion criteria: * Between ages 18 and 65 * No history of cardiovascular or pulmonary disease (previously diagnosed or indicated by EKG, spirometry, and other medical history) * No history of high altitude pulmonary or cerebral edema (HAPE or HACE) * No history of obstructive or central sleep apnea * No current use of anti-inflammatory medication, steroids, stimulants, or other agents that may interfere with ventilatory chemosensitivity * No current pregnancy * No travel above 8,000 feet elevation within 1 month of the first measures * Non-smokers (including any type of vape use, marijuana usage) * No current or recently treated systemic or serious local infection * Must be fluent in the English language * Participants must refrain from consuming alcohol for at least 1 week prior to the start of the study, throughout the duration of their participation, and for 2 days prior to their follow-up visits. * Caffeine and other stimulants may not be consumed during the course of participation in the high-altitude portion of the study (including 12 hours before sea level baseline measures, then starting 2 days before ascent and ending upon return to sea level). * Strenuous physical activity including hiking to higher elevations is not permitted during the high altitude portion of the study.